No Data
No Data
No Data
No Data
No Data
Ascentage Pharma to Present Four Studies at US Oncology Meet
Ascentage Pharma Group International (HKG:6855) will present data from four studies at an oncology meeting in the US from May 31 to June 4, according to a Thursday filing with the Hong Kong bourse. Th
MT NewswiresApr 25 05:18 ET
Yasheng Pharmaceutical-B (06855): Four studies were selected for the ASCO Annual Meeting, and the latest progress of Nellick's treatment of SDH-deficient GIST was presented orally
Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. Four clinical studies of the company's three key varieties were selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and one of them received an oral report. These three key varieties are the first and only third-generation BCR-ABL inhibitor approved for marketing in China, olebatinib (HQP1351; trade name: Nelick), the Bcl-2 selective inhibitor APG-2575, and the FAK/ALK/ROS1 triple inhibitor APG-2449. The annual ASCO annual conference is the field of global oncology
Zhitong FinanceApr 24 19:02 ET
亞盛醫藥-B:2023年報
Futu NewsApr 15 06:12 ET · Announcements
Ascentage Pharma Chairman Boosts Stake in Firm
Ascentage Pharma Group International (HKG:6855) Chairman Yang Dajun acquired an additional 80,000 ordinary shares in the company for approximately HK$1.4 million or HK$17.08 apiece. According to the f
MT NewswiresApr 9 08:37 ET
Yasheng Pharmaceutical-B (06855): Company executives continue to increase their holdings to boost confidence
On April 7, Beijing, Guangzhou, and Zhuhai published documents relating to “Supporting the High-Quality Development of Innovative Pharmaceuticals”. This is only 26 days since the March 13 “Draft for Comments on the Implementation Plan for Full-Chain Support to Support the Development of Innovative Drugs” document went out of the market. In other words, the domestic innovative drug sector felt the strength and warmth of “full chain support” on the policy side in less than a month, reflecting the determination of the regulatory authorities to vigorously develop the innovative drug industry. On April 3 of this year, Yasheng Pharmaceutical was subscribed by Dr. Yang Dajun, the executive director and chairman of the board of directors, and Dr. Wang Shaomeng, the director, for a total of 230,000 shares, equivalent to 41
Zhitong FinanceApr 9 00:53 ET
Yasheng Pharmaceutical-B obtained Executive Director and Chairman Yang Dajun to increase its shareholding by 80,000 shares
Yasheng Pharmaceutical-B (06855) announced that the company was informed by Yang Dajun, the company's executive director and chairman of the board of directors, that on April 5, 2024 and April 8, 2024, he subscribed for a total of 80,000 shares of the company's common shares on the market. The total cost was about HK$1,3662 million. The average price was about HK$17.08 per share, accounting for about 0.028% of the company's total issued share capital at the date of this announcement. On the date of this announcement, according to Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, Dr. Yeung was deemed to have used his rights as a beneficial owner, rights held jointly with other persons, and spousal rights
新浪港股Apr 8 19:36 ET
No Data
No Data